Perspective Therapeutics Inc. Share Price Today: Live Updates & Key Insights

Perspective Therapeutics Inc. share price today is $4.45, up -3.26%. The stock opened at $4.6 against the previous close of $4.6, with an intraday high of $4.77 and low of $4.405.

Perspective Therapeutics Inc. Share Price Chart

Perspective Therapeutics Inc.

us-stock
To Invest in {{usstockname}}
us-stock

Perspective Therapeutics Inc. Share Price Performance

$4.45 -0.0326(-3.26%) CATX at 23 Mar 2026 12:22 PM Medical Devices
Lowest Today 4.405
Highest Today 4.77
Today’s Open 4.6
Prev. Close 4.6
52 Week High 6.16
52 Week Low 1.60
Day’s Range: Low 4.405 High 4.77
52-Week Range: Low 1.60 High 6.16
1 day return -
1 Week return -15.26
1 month return -20.43
3 month return +54.7
6 month return +35.15
1 year return +77.6
3 year return -31.21
5 year return -65.03
10 year return -

Perspective Therapeutics Inc. Institutional Holdings

Perspective Therapeutics Inc. Market Status

Strong Buy: 10

Buy: 3

Hold: 1

Sell: 0

Strong Sell: 0

Perspective Therapeutics Inc. Fundamentals

Market Cap 507.00 M

PB Ratio 2.4489

PE Ratio 0.0

Enterprise Value 365.52 M

Total Assets 266.97 M

Volume 7432675

Perspective Therapeutics Inc. Company Financials

Annual Revenue FY23:0 0.0M, FY23:7104000 7.1M, FY22:10795000 10.8M, FY21:10053000 10.1M, FY20:9680000 9.7M

Annual Profit FY23:null 0.0M, FY23:1634000 1.6M, FY22:4616000 4.6M, FY21:5121000 5.1M, FY20:5124000 5.1M

Annual Net worth FY23:-46508000 -46.5M, FY23:-14670000 -14.7M, FY22:-7153000 -7.2M, FY21:-3188000 -3.2M, FY20:-3269000 -3.3M

Quarterly Revenue Q3/2025:209000 0.2M, Q2/2025:290000 0.3M, Q1/2025:342000 0.3M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:-566000 -0.6M, Q2/2025:-443000 -0.4M, Q1/2025:-390000 -0.4M, Q3/2024:null 0.0M, Q2/2024:null 0.0M

Quarterly Net worth Q3/2025:-25969000 -26.0M, Q2/2025:-21485000 -21.5M, Q1/2025:-18177000 -18.2M, Q3/2024:-15122000 -15.1M, Q2/2024:-11704000 -11.7M

About Perspective Therapeutics Inc. & investment objective

Company Information Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha. The company also develops Pluvicto, a betaemitting radioligand therapy to treat progressive prostate-specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer. It has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 2004 and is headquartered in Seattle, Washington.

Organisation Medical Devices

Employees 163

Industry Medical Devices

CEO Mr. Johan M. Spoor

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Perspective Therapeutics Inc. FAQs

What is the share price of Perspective Therapeutics Inc. today?

The current share price of Perspective Therapeutics Inc. is $4.45.

Can I buy Perspective Therapeutics Inc. shares in India?

Yes, Indian investors can buy Perspective Therapeutics Inc. shares by opening an international trading and demat account with Motilal Oswal.

How to buy Perspective Therapeutics Inc. shares in India?

You can easily invest in Perspective Therapeutics Inc. shares from India by:

Can I buy fractional shares of Perspective Therapeutics Inc.?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Perspective Therapeutics Inc.?

Perspective Therapeutics Inc. has a market cap of $507.00 M.

In which sector does Perspective Therapeutics Inc. belong?

Perspective Therapeutics Inc. operates in the Medical Devices sector.

What documents are required to invest in Perspective Therapeutics Inc. stocks?

To invest, you typically need:

What is the PE and PB ratio of Perspective Therapeutics Inc.?

The PE ratio of Perspective Therapeutics Inc. is N/A and the PB ratio is 2.45.